LB PHARMACEUTICALS INC (LBRX)
Health Care · biopharmaceuticals · NASDAQ
A biopharmaceutical company developing LB-102, a novel, late-stage benzamide antipsychotic candidate targeting schizophrenia and mood disorders.
What LB PHARMACEUTICALS INC does
LB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders. Its lead product candidate, LB-102, is a methylated derivative of the antipsychotic drug amisulpride that is currently in clinical trials for the treatment of schizophrenia, bipolar depression, and as an adjunctive therapy for major depressive disorder.
Themes: neuropsychiatric disorders, schizophrenia, bipolar depression, major depressive disorder, antipsychotics
Fundamentals
- Price$39.23 as of 2026-10-21 close
- Market cap$1.3B as of 2026-08-05 (share count; price 2026-10-21)
- 1-year return+145.2% 2025-10-21 close $16.00 → 2026-10-21 close $39.23
- P/En/a negative earnings
- ROE-8.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.56 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How LBRX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$52M | -$1.71 | -$38M† | $363000† |
| Q1 FY2026 2026-03-31 | -$19M | -$0.67 | -$23M | $32000 |
| Q4 FY2025 2025-12-31 | -$11M† | $3.13† | -$18M† | $40000† |
| Q3 FY2025 2025-09-30 | -$4M | -$0.61 | -$3M† | $0† |
| Q2 FY2025 2025-06-30 | -$5M | -$13.58 | -$6M† | -$9000† |
| Q1 FY2025 2025-03-31 | -$5M | -$14.79 | -$8M | $21000 |
| Q4 FY2024 2024-12-31 | -$5M† | -$14.00† | -$6M† | $238000† |
| Q3 FY2024 2024-09-30 | -$14M | -$39.49 | — | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$283M
- Short-term investments$45M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How LB PHARMACEUTICALS INC looks technically
LB PHARMACEUTICALS INC (LBRX) is trading 24.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average has held above its 200-day average for at least 71 trading days — a long-sustained "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 6 trading days ago. It is 21.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 24.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +24.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $42.41 | $42.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.56 | $31.56 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 33.13. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 71 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 71 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($33.13 to $41.42) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 73.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $50.16 | $50.16 |
|---|---|---|
| From the 52-week high | it is 21.8% below its 52-week high (its highest price of the past year) | -21.8% |
| Above the 52-week low | it is 174.0% above its 52-week low (its lowest price of the past year) | +174.0% |
| Below the 52-week high | it is 21.8% below its highest point of the past year | 21.8% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $50.16 (set on 2026-08-25) | $50.16 |
| Given back of the 52-week move | over the past year its closes ranged ($14.61 to $49.48), and it has given back roughly a quarter of its rise from last year’s low — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.81 to $27.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 29.4% |
| From the all-time high | it is 21.8% below its all-time high | -21.8% |
| Nearest price level | it is trading 15.0% above a support level at $33.36 — a price it turned at three times since 2026-04-27, most recently on 2026-10-08. Since 2025-09-11 it has 7 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -15.0% |
| All-time low | its lowest closing price on record is $13.36 (set on 2025-09-26) | $13.36 |
| Above the all-time low | it is 193.6% above its all-time low | +193.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 33rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.40 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.40 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $33.04 and $40.46 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $33.04 – $36.75 – $40.46 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges above its 200-day average price (24.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.59× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.04 toward buy |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 44 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.7 percentage points (the stock lost 8.7% while the market lost 0.1%) | -8.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 18.1 percentage points (the stock gained 21.4% while the market gained 3.3%) | +18.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 13.6 percentage points (the stock gained 23.4% while the market gained 9.8%) | +13.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 130.0 percentage points (the stock gained 145.2% while the market gained 15.2%) | +130.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 16.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -1.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $33.27 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +17.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $41.20 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -4.8% |
Price levels it has turned at before
LBRX last closed at $39.23 on 2026-10-21. Since 2025-09-11 it has turned at 7 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $33.36 | Support | 15.0% below the last close | turned there three times · 2026-04-27 to 2026-10-08 |
| $50.05 | Resistance | 27.6% above the last close | turned there twice · 2026-08-25 to 2026-09-02 |
| $27.42 | Support | 30.1% below the last close | turned there three times · 2026-03-16 to 2026-06-16 |
| $24.36 | Support | 37.9% below the last close | turned there twice · 2026-01-23 to 2026-04-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $33.13.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $53.93 and $66.78 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $33.13.
This reading has stood for 5 trading days, since 2026-10-15.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$58.00 range $35.00 – $80.00; median $55.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LBRX
- Consensus EPS estimate-$1.52 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.044 from -$1.56, on 2026-09-12, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the successful development and regulatory approval of a single lead product candidate, LB-102.","Significant competition from established pharmaceutical companies with greater resources and marketed antipsychotic products.","Risk that clinical trial results may not support regulatory approval or favorable market positioning."]
What changed in the latest 10-Q
AI-assisted comparison of LBRX's 10-Q filed 2026-08-11 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- The newer filing adds a sentence describing a July 2026 private placement financing with total gross proceeds of $150.0 million before deducting transaction-related expenses.
- The newer filing adds a statement that the company is enrolling in the outpatient, open label NOVA-3 trial (versus 'running' in the older filing).
- The newer filing introduces a specific reference to a planned Phase 2 clinical trial in major depressive disorder using the abbreviation 'aMDD' where the older filing used 'MDD'.
- The newer filing adds discussion of a long-acting injectable ('LAI') formulation of LB-102, which was absent from the older text.
- Removed:
- The older filing contains a cash runway statement: 'We anticipate that based on our current plans, our current cash, cash equivalents and marketable securities will support our planned operations into the second quarter of 2029.' This sentence is absent from the newer filing.
- The older filing contains a pipeline footnote '* Subject to positive Phase 3 data.' that is absent from the newer filing.
- The older filing contains a bulleted list of anticipated operating expense increases (continuing clinical development of LB-102, advancing additional product candidates, etc.). The newer text is truncated and does not show these bullets.
- Reworded:
- The newer filing changed the company description from 'late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders' to 'neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases.'
- The newer filing changed the MDD abbreviation from 'MDD' to 'aMDD' and added a definition for the abbreviation.
- The newer filing revised the description of NOVA-3 from 'running an outpatient, open label trial (NOVA-3)' to 'enrolling an outpatient, open label trial (NOVA-3)' and changed 'required by FDA at the time of approval' to 'required by FDA for an NDA approval.'
- The newer filing changed the description of pipeline expansion for additional LB-102 indications: the older filing stated 'In the future, additional expansion opportunities for LB-102 may include predominantly negative symptoms of schizophrenia, Alzheimer's disease psychosis and agitation, as well as other neuropsychiatric diseases'; the newer filing states these are 'planned' and adds 'with strong mechanistic rationale and validating clinical and real-world experience from amisulpride, potentially including negative symptoms of schizophrenia (with potential for trial initiation in the second half of 2027, subject to regulatory feedback and other factors) and Alzheimer's disease agitation/psychosis.'
- The newer filing changed the description of the heritage of experience supporting continued development of LB-102 from 'heritage of clinical experience with amisulpride' to 'heritage of clinical and real-world experience with amisulpride.'
- The newer filing revised the branded antipsychotic market discussion: the older text stated 'several of these branded drugs each generate U.S. sales greater than $1 billion annually'; the newer text states 'with some approaching between $2 billion to $4 billion in annual U.S. sales.'
- The newer filing revised the residual symptoms wording: the older text said 'persistent residual symptoms—across both psychosis and mood disorders—that continue to impair functioning'; the newer text says 'persistent residual symptoms such as anhedonia and cognitive impairment that continue to impact functioning.'
- The newer filing changed net proceeds from the February 2026 private placement from approximately $93.8 million to approximately $93.7 million.
- The newer filing changed the phrase 'after deducting financial advisory and other financing' to 'after deducting financial advisory and other financing costs.'
- The newer filing updated financial figures: net losses for the six months ended June 30, 2026 and 2025 of $70.7 million and $10.2 million versus net losses for the three months ended March 31, 2026 and 2025 of $19.1 million and $5.3 million; accumulated deficit as of June 30, 2026 of $200.2 million versus accumulated deficit as of March 31, 2026 of $148.6 million.
- The newer filing changed the reference from 'net losses were... for the three months ended March 31, 2026 and 2025' to 'net losses were... for the six months ended June 30, 2026 and 2025.'
- Notes:
- The newer filing text is truncated at the end after 'We expect to continue to generate operating losses and negative operating cash f' and therefore does not include the full remainder of the MD&A section.
- The older filing text is also truncated after '• requi' and does not include the full remainder of the MD&A section.
- The pipeline summaries and tables included in the source filings could not be compared because they are represented as images or omitted from the provided text.
Risk Factors
- Added:
- Newer filing (2026-08-11) adds the six months ended June 30, 2026 net loss figure of approximately $70.7 million.
- Removed:
- Older filing (2026-05-12) contains the three months ended March 31, 2026 net loss figure of approximately $19.1 million, which is not present in the newer filing.
- Reworded:
- The net loss disclosure changed from "For the three months ended March 31, 2026, our net loss was approximately $19.1 million" (older filing, 2026-05-12) to "For the three and six months ended June 30, 2026, our net loss was approximately $51.6 million and $70.7 million, respectively" (newer filing, 2026-08-11).
- The accumulated deficit disclosure changed from "As of March 31, 2026, we had an accumulated deficit of approximately $148.6 million" (older filing, 2026-05-12) to "As of June 30, 2026, we had an accumulated deficit of approximately $200.2 million" (newer filing, 2026-08-11).
- The Table of Contents page number reference changed from 30 (older filing, 2026-05-12) to 32 (newer filing, 2026-08-11).
- Notes:
- The provided text excerpts are truncated mid-sentence in both filings, so only the visible portions were compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LBRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding LBRX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 3,957,178
- Reported value $128,430,225
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LBRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LBRX had 6,010,646 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LBRX had 18.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.51 days to cover at the same settlement.
- Reported short interest (shares) 6,010,646
- Short interest (% of shares outstanding) 18.6%
- Prior settlement (shares) 5,617,182
- Reported change 7%
- Days to cover (reported) 14.51
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Otsuka Pharmaceutical (TYO: 4578)
- Alkermes (ALKS)
- AbbVie (ABBV)
- Acadia Pharmaceuticals (ACAD)
- Lundbeck (CPH: LUN)
- Teva Pharmaceutical (TEVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LBRX vs…
Frequently asked questions
What does LB PHARMACEUTICALS INC (LBRX) do?
LB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders. Its lead product candidate, LB-102, is a methylated derivative of the antipsychotic drug amisulpride that is currently in clinical trials for the treatment of schizophrenia, bipolar depression, and as an adjunctive therapy for major depressive disorder.
What sector is LB PHARMACEUTICALS INC (LBRX) in?
LB PHARMACEUTICALS INC (LBRX) is classified in the Health Care sector. Its industry is biopharmaceuticals. It trades on NASDAQ.
Who are LB PHARMACEUTICALS INC's (LBRX) competitors?
Notable peers of LB PHARMACEUTICALS INC (LBRX) include Otsuka Pharmaceutical (TYO: 4578), Alkermes, AbbVie, Acadia Pharmaceuticals and Lundbeck (CPH: LUN). This peer set is informational only — not financial advice.
Is LB PHARMACEUTICALS INC (LBRX) overbought or oversold right now?
LB PHARMACEUTICALS INC (LBRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LBRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.